Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904591 | 1.00 | BACE1 (0.52) | BACE1BACE2CYP2D6 | |
| SCHEMBL18623924 | 0.93 | BACE1 (0.52) | BACE1BACE2CYP2D6 | |
| SCHEMBL17169203 | 0.89 | BACE1 (0.42) | BACE1BACE2CYP2D6 | |
| SCHEMBL18623925 | 0.89 | BACE1 (0.43) | BACE1BACE2CYP2D6 | |
| SCHEMBL18623876 | 0.86 | BACE1 (0.41) | BACE1BACE2CYP2D6 | |
| SCHEMBL15904467 | 0.84 | BACE1 (0.55) | BACE1BACE2CYP2D6 | |
| SCHEMBL15904438 | 0.84 | BACE1 (0.55) | BACE1BACE2CYP2D6 | |
| SCHEMBL15904516 | 0.84 | BACE1 (0.55) | BACE1BACE2CYP2D6 | |
| SCHEMBL15904509 | 0.84 | BACE1 (0.40) | BACE1BACE2CYP2D6 | |
| SCHEMBL15662011 | 0.83 | BACE1 (0.57) | BACE1BACE2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | WOLTERING THOMAS (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | WOLTERING THOMAS (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | WOLTERING THOMAS (US) | 2015-12-31 | — | — | US | disclosed |
| EP-2948446-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114532-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114532-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885CYP2D6 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.